Peripheral neuropathy can be caused by compression of a nerve (like carpal tunnel syndrome), physical injury to a nerve such ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine sparsentan (Filspari) to treat ...

There was no treatment effect of durvalumab across all subgroups ... creatinine clearance <60 mL/min, hearing impairment, ...

No statistical difference was reported in time to onset of CIPN between the 2 groups. Additionally, 75% of the patients undergoing treatment with gemcitabine plus albumin-bound paclitaxel did not ...

University of California, San Diego-led research suggests that long-term variability in blood pressure is associated with ...

NORTH CHICAGO, IL, USA I 18, 2024 I AbbVie (NYSE: ABBV) today announced the European Commission (EC) granted marketing authorization for ELAHERE® ...

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, ...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

Intellia Therapeutics ( (NTLA) ) just unveiled an announcement.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top ...

Laser therapies may help with pain after a root canal, but a review of published studies shows their effectiveness can vary significantly. Further research is needed to identify the optimal approach.

For columnist Leigh Anne Nelson, multiple sclerosis has resulted in numbness, tingling, and a lack of coordination in her ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has released positive new clinical data from the ongoing phase 1 trial of Nexiguran Ziclumeran (Nex-Z), also known as NTLA-2001, in patients with ...